Star Equity (STRR) 10-Q 8 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 29, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	0000707388
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Outstanding (in shares)		20,309,908
Entity Emerging Growth Company	false
Entity Small Business	true

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Revenues	$ 21,602	$ 22,791
Total revenues	23,912	25,465
Cost of revenues:
Cost of revenues	19,931	20,858
Gross profit	3,981	4,607
Operating expenses:
Marketing and sales	1,143	1,467
General and administrative	3,690	4,392
Amortization of intangible assets	283	357
Total operating expenses	5,116	6,216
Loss from operations	(1,135)	(1,609)
Other expense, net
Other expense, net	(198)	(17)
Interest expense, net	(181)	(217)
Loss on extinguishment of debt	(151)	0
Total other expense	(530)	(234)
Loss before income taxes	(1,665)	(1,843)
Income tax benefit	8	455
Net loss from continuing operations	(1,657)	(1,388)
Net income from discontinued operations	0	5,494
Net (loss) income	$ (1,657)	$ 4,106
Net (loss) income per share—basic and diluted
Continuing operations (in usd per share)	$ (0.08)	$ (0.07)
Discontinued operations (in usd per share)	0	0.27
Net (loss) income per share—basic and diluted (in usd per share)	(0.08)	0.20
Dividends declared per common share (in usd per share)	$ 0	$ 0.055
Other comprehensive (loss) income:
Reclassification of tax provision impact	$ 22	$ 0
Reclassification of unrealized gains on equity securities to retained earnings	0	(17)
Total other comprehensive income (loss)	22	(17)
Comprehensive (loss) income	(1,635)	4,089
Services
Revenues:
Revenues	21,389	22,623
Cost of revenues:
Cost of revenues	18,194	19,261
Product and product-related
Revenues:
Revenues	2,523	2,842
Cost of revenues:
Cost of revenues	$ 1,737	$ 1,597

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 797	$ 1,545
Equity securities	17	153
Accounts receivable, net	13,361	12,642
Inventories, net	5,483	5,402
Restricted cash	168	167
Other current assets	1,522	1,285
Total current assets	21,348	21,194
Property and equipment, net	20,575	21,645
Operating lease right-of-use assets, net	3,681
Intangible assets, net	4,944	5,228
Goodwill	1,745	1,745
Restricted cash	101	101
Deferred tax assets	16	0
Other assets	2,183	681
Total assets	54,593	50,594
Current liabilities:
Accounts payable	4,808	5,206
Accrued compensation	3,246	3,862
Accrued warranty	230	197
Deferred revenue	1,414	1,687
Operating lease liabilities	1,251
Other current liabilities	2,474	2,265
Total current liabilities	13,423	13,217
Long-term debt	12,517	9,500
Deferred tax liabilities	121	121
Operating lease liabilities, net of current portion	2,564
Other liabilities	1,715	1,956
Total liabilities	30,340	24,794
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 20,309,908 and 20,249,786 shares issued and outstanding (net of treasury shares) at March 31, 2019 and December 31, 2018, respectively	2	2
Treasury stock, at cost; 2,588,484 shares at March 31, 2019 and December 31, 2018	(5,728)	(5,728)
Additional paid-in capital	145,516	145,428
Accumulated other comprehensive loss	0	(22)
Accumulated deficit	(115,537)	(113,880)
Total stockholders’ equity	24,253	25,800
Total liabilities and stockholders’ equity	$ 54,593	$ 50,594

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	80,000,000	80,000,000
Common stock, issued (in shares)	20,309,908	20,249,786
Common stock, outstanding (in shares)	20,309,908	20,249,786
Treasury stock (in shares)	2,588,484	2,588,484

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net (loss) income	$ (1,657)	$ 4,106
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,526	1,910
Amortization of intangible assets	283	370
Amortization of operating lease right-of-use assets	276
Provision for bad debt	75	13
Gain on disposal of discontinued operations	0	(6,261)
Stock-based compensation	112	200
Amortization of loan issuance costs	8	54
Debt issuance costs write-off	151	0
(Gain) loss on sale of assets	(42)	5
Deferred income taxes	(16)	107
Other, net	(28)	17
Changes in operating assets and liabilities:
Accounts receivable	(794)	3,119
Inventories	8	(177)
Other assets	(454)	185
Accounts payable	(664)	21
Accrued compensation	(616)	(2,299)
Deferred revenue	(273)	(568)
Operating lease liabilities	(287)
Other liabilities	207	(382)
Net cash (used in) provided by operating activities	(2,185)	420
Investing activities
Purchases of property and equipment	(387)	(201)
Proceeds from sale of property and equipment	257	40
Purchases of equity securities	0	(14)
Proceeds from sales of equity securities	140	0
Proceeds from sale of discontinued operations	0	6,844
Payments to acquire interest in joint ventures	(1,000)	0
Net cash (used in) provided by investing activities	(990)	6,669
Financing activities
Proceeds from long-term borrowings	23,517	7,758
Repayment of long-term debt	(20,500)	(14,257)
Loan issuance costs	(381)	(4)
Dividends paid	0	(1,105)
Taxes paid related to net share settlement of equity awards	(24)	(70)
Repayment of obligations under finance leases	(184)	(254)
Net cash provided by (used in) financing activities	2,428	(7,932)
Net decrease in cash and cash equivalents and restricted cash	(747)	(843)
Cash, cash equivalents, and restricted cash at beginning of period	1,813	2,220
Cash, cash equivalents, and restricted cash at end of period	$ 1,066	$ 1,377

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common stock	Treasury Stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2017		20,060,000
Beginning balance at Dec. 31, 2017	$ 27,799	$ 2	$ (5,728)	$ 148,163	$ (5)	$ (114,633)
Stock-based compensation	200			200
Shares issued under stock incentive plans, net of shares withheld for employee taxes (in shares)		59,000
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(69)			(69)
Dividends paid	(1,105)			(1,105)
Net (loss) income	4,106
Unrealized loss on securities available-for-sale	0				(17)	17
Ending balance (in shares) at Mar. 31, 2018		20,119,000
Ending balance at Mar. 31, 2018	$ 30,931	$ 2	(5,728)	147,189	(22)	(110,510)
Beginning balance (in shares) at Dec. 31, 2018	20,249,786	20,250,000
Beginning balance at Dec. 31, 2018	$ 25,800	$ 2	(5,728)	145,428	(22)	(113,880)
Stock-based compensation	112			112
Shares issued under stock incentive plans, net of shares withheld for employee taxes (in shares)		60,000
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(24)			(24)
Net (loss) income	(1,657)
Reclassification of tax provision impact	$ 22				22
Ending balance (in shares) at Mar. 31, 2019	20,309,908	20,310,000
Ending balance at Mar. 31, 2019	$ 24,253	$ 2	$ (5,728)	$ 145,516	$ 0	$ (115,537)

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2018 , filed with the SEC on Form 10-K on March 1, 2019 , include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Discontinued Operations On February 1, 2018, the Company completed the sale of its customer contracts relating to the Medical Device Sales and Service (“MDSS”) post-warranty service business to Philips North America LLC (“Philips”) pursuant to an Asset Purchase Agreement, dated as of December 22, 2017 for $8.0 million . For all periods presented in our condensed consolidated statements of operations, all sales, costs, expenses, and income taxes attributable to MDSS, except as related to the impact of the decrease in the federal statutory tax rate (see Note 10 Income Taxes ), have been aggregated under the caption “earnings from discontinued operations, net of income taxes.” Cash flows used in or provided by MDSS operations as part of discontinued operations are disclosed in Note 2 Discontinued Operations . Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate to our continuing operations. Sale of Telerhythmics, LLC On October 31, 2018, the Company entered into a membership interest purchase agreement (the “Telerhythmics Purchase Agreement”) with G Medical Innovations USA, Inc. (“G Medical”), pursuant to which we sold all the outstanding membership interests in Telerhythmics (“Telerhythmics”) to G Medical. The total consideration related to the Telerhythmics Purchase Agreement was $1.95 million in cash, which was paid at the closing on October 31, 2018. In connection with the transaction, the Company agreed to make partial monthly rent payments aggregating $0.2 million through January 2021. The Telerhythmics Purchase Agreement includes customary representations, warranties, covenants and indemnification obligations of the parties, including a non-competition covenant by the Company. The gain on the sale of Telerhythmics, LLC was approximately $19 thousand . Use of Estimates Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit discount rate when readily determinable; however, as most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease valuation may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components of its operating leases in which it is the lessee and lessor. Additionally, The Company elected not to recognize right-of use assets and leases liabilities that arise from short-term leases of twelve months or less. Recently Adopted Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amended the existing accounting standards for the accounting for leases. Most significant among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases under current U.S. GAAP. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted ASC 842 beginning January 1, 2019, using the modified-retrospective method, which will result in a cumulative effect adjustment to accumulated deficit at the beginning of 2019, rather than adjustments to the comparative prior periods presented in the financial statements. In connection with the adoption, the Company has elected to utilize the package of practical expedients, including: (1) not reassess the lease classification for any expired or existing leases, (2) not reassess the treatment of initial direct costs as they related to existing leases, and (3) not reassess whether expired or existing contracts are or contain leases. Upon adoption, the Company recorded right-of-use assets and lease liabilities on its condensed consolidated balance sheet $3.8 million and $3.9 million , respectively, primarily related to real estate and vehicle leases. See Note 6 Leases for further detail. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company early adopted ASU 2018-15 beginning January 1, 2019, and applied the guidance prospectively to the implementation costs incurred in the Net-Suite ERP implementation. As of March 31, 2019 , the Company has capitalized $29 thousand of implementation costs.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On February 1, 2018 , the Company completed the sale of its customer contracts relating to our MDSS post-warranty service business to Philips pursuant to an Asset Purchase Agreement, dated as of December 22, 2017, for $8.0 million . The total cash proceeds were adjusted for deferred revenue liabilities assigned to Philips at the closing date, as well as $0.5 million of proceeds held in escrow, subject to claims for breaches of general representation and warranties, which was recorded in other current assets at the date of sale. All claims were settled as of December 31, 2018 . Prior to the contemplation of the transaction entered into above, on September 28, 2017 , we received notification from Philips that our distribution agreement to sell Philips imaging systems on a commission basis would be terminated, effective December 31, 2017 . As a result, our product sales activities within our MDSS reportable segment were also discontinued effective in the first quarter of 2018 . The Company deemed the disposition of our MDSS reportable segment in the first quarter of 2018 to represent a strategic shift that will have a major effect on our operations and financial results, in accordance with the provisions of FASB authoritative guidance on the presentation of financial statements, we have classified the results of our MDSS segment as discontinued operations in our condensed consolidated statement of operations for all periods presented. The Company has allocated a portion of interest expense to discontinued operations since the proceeds received from the sale were required to be used to pay down outstanding borrowings under our previous revolving credit facility with Comerica Bank, a Texas banking association (“Comerica Bank”) under that certain Revolving Credit Agreement, dated June 21, 2017, by and between the Company and Comerica Bank (the “Comerica Credit Agreement”). The allocation was based on the ratio of proceeds received in the sale to total borrowings for the period. In addition, certain general and administrative costs related to corporate and shared service functions previously allocated to the MDSS reportable segment are not included in discontinued operations. The following table presents financial results of the MDSS business (in thousands): Three Months Ended March 31, 2019 2018 Total revenues $ — $ 624 Total cost of revenues — 516 Gross profit — 108 Operating expenses: Marketing and sales — 85 General and administrative — 172 Amortization of intangible assets — 13 Gain on sale of discontinued operations — (6,261 ) Total operating expenses — (5,991 ) Income from discontinued operations — 6,099 Interest expense — (26 ) Income from discontinuing operations before income taxes — 6,073 Income tax expense — (579 ) Income from discontinuing operations $ — $ 5,494 The following table presents supplemental cash flow information of discontinued operations (in thousands): Three Months Ended March 31, 2019 2018 Operating activities: Depreciation $ — $ 2 Amortization of intangible assets $ — $ 13 Gain on sale of discontinued operations $ — $ (6,261 ) Stock-based compensation $ — $ (1 ) Investing activities: Proceeds from the sale of discontinued operations $ — $ 6,844

Revenue

Revenue	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Product and Product-Related Revenues and Services Revenue Product and product-related revenue are generated from the sale of gamma cameras and post-warranty maintenance service contracts within our Diagnostic Imaging reportable segment. Services revenue are generated from providing diagnostic imaging and cardiac monitoring services to customers within our Diagnostic Services and Mobile Healthcare reportable segments. Services revenue also includes lease income generated from interim rentals of imaging systems to our customers. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. The majority of our contracts have a single performance obligation as we provide a series of distinct services that are substantially the same and are transferred with the same pattern to the customer. For contracts with multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. Our products are generally not sold with a right of return and the Company does not provide significant credits or incentives, which may be required for as variable consideration when estimating the amount of revenue to be recognized. Disaggregation of Revenue The following tables present our revenues for the three months ended March 31, 2019 and 2018 , disaggregated by major source (in thousands): Three Months Ended March 31, 2019 Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,585 $ — $ 7,494 $ 19,079 Camera — 804 — 804 Camera Support — 1,719 — 1,719 Revenue from Contracts with Customers 11,585 2,523 7,494 21,602 Lease Income 141 — 2,169 2,310 Total Revenues $ 11,726 $ 2,523 $ 9,663 $ 23,912 Timing of Revenue Recognition Services and goods transferred over time $ 11,726 $ 1,551 $ 9,525 $ 22,802 Services and goods transferred at a point in time — 972 138 1,110 Total Revenues $ 11,726 $ 2,523 $ 9,663 $ 23,912 Three Months Ended March 31, 2018 Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,898 $ — $ 8,079 $ 19,977 Camera — 1,070 — 1,070 Camera Support — 1,744 — 1,744 Revenue from Contracts with Customers 11,898 2,814 8,079 22,791 Lease Income 127 28 2,519 2,674 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Timing of Revenue Recognition Services and goods transferred over time $ 10,964 $ 1,720 $ 10,491 $ 23,175 Services and goods transferred at a point in time 1,061 1,122 107 2,290 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Nature of Goods and Services Mobile Imaging Within our Diagnostic Services and Mobile Healthcare reportable segments, our sales are derived from providing services and materials to our customers, primarily physician practices and hospitals, that allow them to perform diagnostic imaging services at their site. We typically bundle our services in providing staffing, our imaging systems, licensing, radiopharmaceuticals, and supplies depending on our customers’ needs. Our contracts with customers are typically entered into annually and are billed on a fixed rate per-day or per-scan basis, depending on terms of the contract. For the majority of these contracts, the Company has the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company’s performance to date. The Company uses the practical expedient to recognize revenue corresponding with amounts we have the right to invoice for services performed. Camera Within our Diagnostic Imaging segment, camera revenues are generated from the sale of internally developed solid-state gamma camera imaging systems. We recognize revenue upon transfer of control to the customer, which is generally upon delivery and acceptance. We also provide installation services and training on cameras we sell, primarily in the United States. Installation and initial training is generally performed shortly after delivery. The Company recognizes revenues for installation and training over time as the customer receives and consumes benefits provided as the Company performs the installation services. Our sale of imaging systems includes a one -year warranty that we account for as an assurance-type warranty. The expected costs associated with our standard warranties and field service actions continue to be recognized as expense when cameras are sold. Maintenance service contracts sold beyond the term of our standard warranties are accounted for as a service-type warranty and revenue is deferred and recognized ratably over the period of the obligation. Camera Support Within our Diagnostic Imaging segment, camera support revenue is derived from the sale of separately-priced extended maintenance contracts to camera owners, training, and the sale of parts to customers that do not have an extended warranty. Our separately priced service contracts range from 12 to 48 months. Service contracts are usually billed at the beginning of the contract period or at periodic intervals (e.g., monthly or quarterly) and revenue is recognized ratably over the term of the agreement. Services and training revenues are recognized in the period the services and training are performed. Revenue for sales of parts are recognized when the parts are delivered to the customer and control is transferred. Lease Income Within primarily our Mobile Healthcare segment, we also generate income from interim rentals of our imaging systems to customers that are in the midst of new construction or refurbishing their current facilities. Rental contracts are structured as either a weekly or monthly payment arrangement and are accounted for as operating leases. Revenues are recognized on a straight-line basis over the term of the rental. Deferred Revenues We record deferred revenues when cash payments are received or due in advance of our performance, including amounts that are refundable. We have determined our contracts do not include a significant financing component. The majority of our deferred revenue relates to payments received on camera support post-warranty service contracts, which are billed at the beginning of the annual contract period or at periodic intervals (e.g., monthly or quarterly). Changes in the deferred revenues for three months ended March 31, 2019 , is as follows (in thousands): Balance at December 31, 2018 $ 1,713 Revenue recognized that was included in balance at beginning of the year (541 ) Deferred revenue, net, related to contracts entered into during the year 262 Balance at March 31, 2019 $ 1,434 Included in the balances above as of March 31, 2019 and December 31, 2018 is non-current deferred revenue of $20 thousand and $26 thousand , respectively. The Company has elected to use the practical expedient under ASC 606 to exclude disclosures of unsatisfied remaining performance obligations for (i) contracts having an original expected length of one year or less or (ii) contracts for which the practical expedient has been applied to recognize revenue at the amount for which it has a right to invoice. Contract Costs We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs mainly include the Company’s internal sales commissions; under the terms of these programs these are generally earned and the costs are recognized at the time the revenue is recognized.

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share, Basic and Diluted [Abstract]
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share For the three months ended March 31, 2019 and 2018 , basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method. In periods for which there is a net loss, diluted loss per common share is equal to basic loss per common share, since the effect of including any common stock equivalents would be antidilutive. The following table sets forth the reconciliation of shares used to compute basic and diluted net (loss) income per share for the periods indicated (in thousands): Three Months Ended March 31, 2019 2018 Loss from continuing operations $ (1,657 ) $ (1,388 ) Income from discontinued operations — 5,494 Net (loss) income $ (1,657 ) $ 4,106 Weighted-average shares outstanding—basic and diluted 20,278 20,092 (Loss) income per common share—basic and diluted Continuing operations $ (0.08 ) $ (0.07 ) Discontinued operations — 0.27 Net (loss)income per common share—basic and diluted $ (0.08 ) $ 0.20 The computation of diluted earnings per share excludes stock options and stock units that are anti-dilutive. The following common stock equivalents were anti-dilutive (in thousands): Three Months Ended March 31, 2019 2018 Stock options 1,000 207 Restricted stock units 287 129 Total 1,287 336

Supplementary Balance Sheet Inf

Supplementary Balance Sheet Information	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Supplementary Balance Sheet Information	Supplementary Balance Sheet Information The components of inventories are as follows (in thousands): March 31, December 31, Inventories: Raw materials $ 2,425 $ 2,419 Work-in-process 2,285 2,307 Finished goods 1,154 1,056 Total inventories 5,864 5,782 Less reserve for excess and obsolete inventories (381 ) (380 ) Total inventories, net $ 5,483 $ 5,402 Property and equipment consist of the following (in thousands): March 31, December 31, 2018 Property and equipment: Land $ 550 $ 550 Buildings and leasehold improvements 1,989 1,989 Machinery and equipment 52,138 52,409 Computer hardware and software 4,489 4,490 Total property and equipment 59,166 59,438 Less accumulated depreciation (38,591 ) (37,793 ) Total property and equipment, net $ 20,575 $ 21,645

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Leases We have operating and finance leases for corporate offices, vehicles, and certain equipment. Our leases have remaining lease terms of 1 year to 6 years , some of which include options to extend the leases and some of which include options to terminate the leases within 1 year . Operating leases are included separately in the condensed consolidated balance sheets and finance leases are included in other current liabilities and other liabilities in the condensed consolidated balance sheets. The components of lease expense are as follows (in thousands): Three Months Ended Operating lease cost $ 326 Finance lease cost: Amortization of finance lease assets $ 53 Interest on finance lease liabilities 33 Total finance lease cost $ 86 Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 287 Operating cash flows from finance leases $ 33 Financing cash flows from finance leases $ 184 Right-of-use assets obtained in exchange for lease obligations Operating leases $ 323 Finance leases $ 145 Supplemental balance sheet information related to leases was as follows (in thousands): March 31, Operating lease right-of-use assets, net $ 3,681 Operating lease liabilities $ 1,251 Operating lease liabilities, net of current 2,564 Total operating lease liabilities $ 3,815 Finance lease assets $ 3,702 Finance lease accumulated amortization (1,100 ) Finance lease assets, net $ 2,602 Finance lease liabilities $ 809 Finance lease liabilities, net of current 1,607 Total finance lease liabilities $ 2,416 Weighted-Average Remaining Lease Term (in years) Operating leases 3.4 Finance leases 2.9 Weighted-Average Discount Rate Operating leases 5.00 % Finance leases 6.00 % We are committed to making future cash payments on non-cancelable operating leases and finance leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2019 were as follows (in thousands): Operating Finance Leases 2019 (excludes the three-months ended March 31, 2019) $ 1,066 $ 696 2020 1,317 842 2021 953 817 2022 552 258 2023 259 10 Thereafter 4 — Total future minimum lease payments $ 4,151 $ 2,623 Less amounts representing interest 336 207 Present value of lease obligations $ 3,815 $ 2,416
Leases	Leases We have operating and finance leases for corporate offices, vehicles, and certain equipment. Our leases have remaining lease terms of 1 year to 6 years , some of which include options to extend the leases and some of which include options to terminate the leases within 1 year . Operating leases are included separately in the condensed consolidated balance sheets and finance leases are included in other current liabilities and other liabilities in the condensed consolidated balance sheets. The components of lease expense are as follows (in thousands): Three Months Ended Operating lease cost $ 326 Finance lease cost: Amortization of finance lease assets $ 53 Interest on finance lease liabilities 33 Total finance lease cost $ 86 Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 287 Operating cash flows from finance leases $ 33 Financing cash flows from finance leases $ 184 Right-of-use assets obtained in exchange for lease obligations Operating leases $ 323 Finance leases $ 145 Supplemental balance sheet information related to leases was as follows (in thousands): March 31, Operating lease right-of-use assets, net $ 3,681 Operating lease liabilities $ 1,251 Operating lease liabilities, net of current 2,564 Total operating lease liabilities $ 3,815 Finance lease assets $ 3,702 Finance lease accumulated amortization (1,100 ) Finance lease assets, net $ 2,602 Finance lease liabilities $ 809 Finance lease liabilities, net of current 1,607 Total finance lease liabilities $ 2,416 Weighted-Average Remaining Lease Term (in years) Operating leases 3.4 Finance leases 2.9 Weighted-Average Discount Rate Operating leases 5.00 % Finance leases 6.00 % We are committed to making future cash payments on non-cancelable operating leases and finance leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2019 were as follows (in thousands): Operating Finance Leases 2019 (excludes the three-months ended March 31, 2019) $ 1,066 $ 696 2020 1,317 842 2021 953 817 2022 552 258 2023 259 10 Thereafter 4 — Total future minimum lease payments $ 4,151 $ 2,623 Less amounts representing interest 336 207 Present value of lease obligations $ 3,815 $ 2,416

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2019 and December 31, 2018 (in thousands). Fair Value as of March 31, 2019 Level 1 Level 2 Level 3 Total Equity securities $ 17 $ 31 $ — $ 48 Fair Value as of December 31, 2018 Level 1 Level 2 Level 3 Total Equity securities $ 153 $ 6 $ — $ 159 The investment in equity securities consists of common stock of publicly traded companies. The level 2 securities are included in other assets on the Company’s condensed consolidated balance sheet. The fair value of these securities is based on the closing prices observed on March 31, 2019 . During the three months ended March 31, 2019 the Company recorded in the condensed consolidated statement of operations an unrealized gain of $28 thousand and immaterial unrealized losses. We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2019 . The fair values of the Company’s revolving credit facility approximate carrying value due to the variable rate nature of these borrowings.

Debt

Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	Debt A summary of long-term debt is as follows (in thousands): March 31, 2019 December 31, 2018 Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Revolving Credit Facility - SNB $ 12,517 5.00% $ — —% Revolving Credit Facility - Comerica $ — —% $ 9,500 4.87% On March 29, 2019, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) by and among certain subsidiaries of the Company, as borrowers (collectively, the “Borrowers”); the Company, as guarantor; and Sterling National Bank, a national banking association, as lender (“SNB”). The Loan Agreement is a five -year credit facility maturing in March 2024, with a maximum credit amount of $20.0 million for both revolving loans and outstanding letter of credit obligations (the “SNB Credit Facility”). Under the SNB Credit Facility, Borrowers can request the issuance of letters of credit in an aggregate amount not to exceed $0.5 million at any one time outstanding. As of March 31, 2019 , the Company had $0.1 million of letters of credit outstanding and had additional borrowing capacity of $7.5 million . At the Borrowers’ option, the SNB Credit Facility will bear interest at either (i) a Floating LIBOR Rate, as defined in the Loan Agreement, plus a margin of 2.50% per annum; or (ii) a Fixed LIBOR Rate, as defined in the Loan Agreement, plus a margin of 2.25% per annum. The Company used a portion of the financing made available under the SNB Credit Facility to refinance and terminate, effective as of March 29, 2019, its previous credit facility under the Comerica Credit Agreement. The Loan Agreement includes certain representations, warranties of Borrowers, as well as events of default and certain affirmative and negative covenants by the Borrowers that are customary for loan agreements of this type. These covenants include restrictions on borrowings, investments and dispositions by Borrowers, as well as limitations on the Borrowers’ ability to make certain distributions. Upon the occurrence and during the continuation of an event of default under the Loan Agreement, SNB may, among other things, declare the loans and all other obligations under the Loan Agreement immediately due and payable and increase the interest rate at which loans and obligations under the Loan Agreement bear interest. The SNB Credit Facility is secured by a first-priority security interest in substantially all of the assets of the Company and the Borrowers and a pledge of all shares of the Borrowers. On March 29, 2019, in connection with the Company’s entry into the SNB Loan Agreement, Mr. Eberwein, the Chairman of the Company’s board of directors, entered into Limited Guaranty Agreement (the “Limited Guaranty”) with SNB pursuant to which he guaranteed to SNB the prompt performance of all the Borrowers’ obligations to SNB under the SNB Loan Agreement, including the full payment of all indebtedness owing by Borrowers to SNB under or in connection with the Loan Agreement and related SNB Credit Facility documents. Mr. Eberwein’s obligations under the Limited Guaranty are limited in the aggregate to the amount of (a) $1.5 million , plus (b) reasonable costs and expenses of SNB incurred in connection with the Limited Guaranty. Mr. Eberwein’s obligations under the Limited Guaranty terminate upon the Company and Borrowers achieving certain milestones set forth therein. In connection with the SNB Credit Facility, in the three months ended March 31, 2019 , the Company recognized a $0.2 million loss on extinguishment due to the write off of unamortized deferred financing costs associated with the Comerica Credit Agreement. At March 31, 2019 , the Company was in compliance with all covenants.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Other Matters In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We provide for income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the financial statements. We provide a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. We calculate the valuation allowance in accordance with the authoritative guidance relating to income taxes, which requires an assessment of both positive and negative evidence regarding the realizability of these deferred tax assets, when measuring the need for a valuation allowance. Significant judgment is required in determining any valuation allowance against deferred tax assets. As of December 31, 2017, as a result of a three-year cumulative loss and recent events, such as the unanticipated termination of the Philips distribution agreement and its effect on our forecasted income, we concluded that a full valuation allowance was necessary to offset our deferred tax assets. We continue to record a full valuation allowance against our deferred tax assets and intend to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. Intraperiod tax allocation rules require us to allocate our provision for income taxes between continuing operations and other categories of comprehensive income, such as discontinued operations. In periods in which we have a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of comprehensive income, such as discontinued operations, we must consider that income in determining the amount of tax benefit that results from a loss in continuing operations and that shall be allocated to continuing operations. For the three months ended March 31, 2019 , the Company recorded an income tax benefit of $8 thousand within continuing operations. As a result of the intraperiod tax allocation rules, for the three months ended March 31, 2018 , the Company recorded an income tax benefit of $0.5 million and $0.6 million of income tax expense within continuing operations and discontinued operations, respectively. As of March 31, 2019 , we had unrecognized tax benefits of approximately $3.6 million related to uncertain tax positions. Included in the unrecognized tax benefits were $3.2 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2014; however, our net operating loss carryforwards and research credit carryforwards arising prior to that year are subject to adjustment. Our policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Segments

Segments	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segments	Segments Our reporting segments have been determined based on the nature of the products and services offered to customers or the nature of their function in the organization. We evaluate performance based on the gross profit and operating income (loss). The Company does not identify or allocate its assets by operating segments. Segment information is as follows (in thousands): Three Months Ended March 31, 2019 2018 Revenue by segment: Diagnostic Services $ 11,726 $ 12,025 Diagnostic Imaging 2,523 2,842 Mobile Healthcare 9,663 10,598 Condensed consolidated revenue $ 23,912 $ 25,465 Gross profit by segment: Diagnostic Services $ 2,581 $ 2,247 Diagnostic Imaging 786 1,245 Mobile Healthcare 614 1,115 Condensed consolidated gross profit $ 3,981 $ 4,607 Loss from continuing operations by segment: Diagnostic Services $ 1,736 $ 993 Diagnostic Imaging 343 619 Mobile Healthcare (623 ) (51 ) Unallocated corporate and other expenses (2,591 ) (3,170 ) Condensed consolidated loss from continuing operations $ (1,135 ) $ (1,609 ) Depreciation and amortization by segment: Diagnostic Services $ 304 $ 596 Diagnostic Imaging 78 74 Mobile Healthcare 1,427 1,592 Total depreciation and amortization $ 1,809 $ 2,262

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Perma-Fix Mr. John Climaco currently serves as a Director of the Company and a member of the Corporate Governance and Strategic Advisory committees of the Board. Until July 11, 2017, Mr. Climaco also served as a Director of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI). Further, from June 2, 2015 until July 11, 2017, Mr. Climaco served as the Executive Vice President of Perma-Fix Medical S.A., a majority-owned Polish subsidiary of Perma-Fix Environmental Services, Inc. On July 27, 2015, we entered into a Stock Subscription Agreement (the “Subscription Agreement”) and Tc-99m Supplier Agreement (the “Supply Agreement”) with Perma-Fix Medical. Under the terms of the Subscription Agreement, we invested $1.0 million USD in exchange for 71,429 shares of Perma-Fix Medical. Pursuant to the Supply Agreement, should Perma-Fix Medical successfully complete development of the new Tc-99m resin, Perma-Fix Medical will supply us or our preferred nuclear pharmacy supplier with Tc-99m at a preferred rate and we will purchase agreed upon quantities of such Tc-99m for our nuclear imaging operations, either directly or in conjunction with our preferred nuclear pharmacy supplier. In addition, in connection with the Subscription Agreement, the Company’s President and CEO was appointed to the Supervisory Board of Perma-Fix Medical. The investment in Perma-Fix is included in other assets in the condensed consolidated balance sheets. Limited Guaranty On March 29, 2019, in connection with the Company’s entry into the Loan Agreement, Mr. Eberwein, the Chairman of the Company’s board of directors, entered into Limited Guaranty Agreement (the “Limited Guaranty”) with SNB pursuant to which he guaranteed to SNB the prompt performance of all the Borrowers’ obligations to SNB under the Loan Agreement, including the full payment of all indebtedness owing by Borrowers to SNB under or in connection with the Loan Agreement and related SNB Credit Facility documents. Mr. Eberwein’s obligations under the Limited Guaranty are limited in the aggregate to the amount of (a) $1.5 million , plus (b) reasonable costs and expenses of SNB incurred in connection with the Limited Guaranty. Mr. Eberwein’s obligations under the Limited Guaranty terminate upon the Company and Borrowers achieving certain milestones set forth therein. ATRM Jeffrey E. Eberwein, the Chairman of our board of directors and the Chairman of the board of directors of ATRM Holdings, Inc., (“ATRM”), owns approximately 17.4% of the outstanding common stock of ATRM. Mr. Eberwein is also the Chief Executive Officer of Lone Star Value Management, LLC, which is the investment manager of Lone Star Value Investors, LP (“LSVI”). LSVI owns 222,577 shares of ATRM’s 10.0% Series B Cumulative Preferred Stock (the “Series B Stock”) and another 374,562 shares of Series B Stock are owned directly by Lone Star Value Co-Invest I, LP (“LSV Co-Invest I”). Through these relationships and other relationships with affiliated entities, Mr. Eberwein may be deemed the beneficial owner of the securities owned by LSVI and LSV Co-Invest I. Mr. Eberwein disclaims beneficial ownership of Series B Stock, except to the extent of his pecuniary interest therein. Joint Venture On December 14, 2018, Digirad and ATRM, entered into a joint venture and formed Star Procurement, LLC (“Star Procurement”), with Digirad and ATRM each holding a 50% interest. The purpose of the joint venture is to provide the service of purchasing and selling building materials and related goods to KBS Builders, Inc., a wholly-owned subsidiary of ATRM with which Star Procurement entered into a Services Agreement on January 2, 2019. In accordance with the terms of the Star Procurement Limited Liability Company Agreement, Digirad made a $1.0 million capital contribution to the joint venture, which was made in January 2019. The investment in Star Procurement is included in other assets in the condensed consolidated balance sheets. Note Receivable On December 14, 2018, the Company received an unsecured promissory note from ATRM in the principal amount of $0.3 million (the “ATRM Note”) in exchange for a loan to ATRM in the same amount. The ATRM Note bears interest at 10% per annum for the first 12 months of its term, and at 12% per annum for the remaining 12 months. All unpaid principal and interest is due on December 14, 2020. ATRM may prepay the note at any time after a specified amount of advance notice to the Company. The ATRM Note provides for customary events of default, the occurrence of any of which may result in the principal and unpaid interest then outstanding becoming immediately due and payable. The ATRM Note is included in other assets in the condensed consolidated balance sheets.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisitions and Leases of Maine Facilities As part of the Company’s previously announced conversion into a diversified holding company (the “HoldCo Conversion”), we formed a real estate subsidiary named Star Real Estate Holdings USA, Inc. (“SRE”). SRE will hold any significant real estate assets we acquire. We expect SRE to be substantially self-funded over time by raising its own capital in the form of commercial mortgages on the properties it owns or by raising other forms of external capital. As an initial transaction to create our real estate division under SRE and launch that aspect of the HoldCo Conversion, we purchased three plants in Maine that manufacture modular buildings and leased these three properties, as further described below. Oxford On March 27, 2019, 56 Mechanic Falls Road, LLC (“56 Mechanic”), a wholly-owned subsidiary of SRE, entered into a Purchase and Sale Agreement (the “Oxford Purchase Agreement”) with RJF - Keiser Real Estate, LLC (“RJF”), pursuant to which 56 Mechanic will purchase certain real property and related improvements and personal property (including buildings, fixtures, and other improvements on the land, and all machinery and equipment and other personal property, if any, owned by RJF and located on the property) located in Oxford, Maine (the “Oxford Facility”) from RJF (the “Oxford Transaction”). The Oxford Transaction was closed on April 25, 2019. The purchase price of the Oxford Facility was $1.2 million (the “Oxford Purchase Price”), subject to adjustment for taxes and other charges and assessments. Waterford On April 3, 2019, 947 Waterford Road, LLC (“947 Waterford”), a wholly-owned subsidiary of SRE, entered into a Purchase and Sale Agreement (the “Waterford Purchase Agreement”) with KBS Builders, Inc. (“KBS”), a wholly-owned subsidiary of ATRM, pursuant to which 947 Waterford closed on the purchase of certain real property and related improvements (including buildings) located in Waterford, Maine (the “Waterford Facility”) from KBS, and acquired the Waterford Facility. The purchase price of the Waterford Facility was $1.0 million , subject to adjustment for taxes and other charges and assessments. Paris On April 3, 2019, 300 Park Street, LLC (“300 Park”), a wholly-owned subsidiary of SRE, entered into a Purchase and Sale Agreement (the “Park Purchase Agreement”) with KBS, pursuant to which 300 Park closed on the purchase of certain real property and related improvements and personal property (including buildings, machinery and equipment) located in Paris, Maine (the “Park Facility”) from KBS, and acquired the Park Facility. The purchase price of the Park Facility was $2.9 million , subject to adjustment for taxes and other charges and assessments. Lease of Maine Facilities On April 3, 2019, KBS entered into a separate lease agreement with each of 947 Waterford (the “Waterford Lease”) and 300 Park (the “Park Lease”). The Waterford Lease has an initial term of 120 months , which is subject to extension. The base rental payments associated with the initial term under the Waterford Lease are estimated to be between $1.2 million and $1.3 million in the aggregate. The Park Lease has an initial term of 120 months , which is subject to extension. The base rental payments associated with the initial term under the Park Lease are estimated to be between $3.3 million and $3.6 million in the aggregate. ATRM has unconditionally guaranteed the performance of all obligations under the Waterford Lease and Park Lease to be performed by KBS under each lease, including, without limitation, the payment of all required rent. On April 3rd and 18th of 2019, KBS signed a lease and an amendment, respectively, with 56 Mechanic (the “Oxford Lease”), which became effective upon the closing of the Oxford Transaction. The initial term under the Oxford Lease will commence upon delivery of the Oxford Facility to KBS. The Oxford Lease has an initial term of 120 months , which is subject to extension. The base rental payments associated with the initial term under the Oxford Lease are estimated to be between $1.4 million and $1.5 million in the aggregate. ATRM has unconditionally guaranteed the performance of all obligations under the Oxford Lease to be performed by KBS, including, without limitation, the payment of all required rent. Series A Preferred Stock Offering The Company has filed a registration statement on Form S-1 and Form S-1/A with the SEC for a potential offering (the “Preferred Offering”) of nonconvertible Series A Cumulative Term Preferred Stock (the “Series A Preferred Stock”) on March 12, 2019 and April 09, 2019, respectively. However, it is unlikely that the Company will proceed with its proposed offering of nonconvertible preferred stock on substantially the terms described in the registration statement. Fargo Building Sale The Company completed the sale on the remaining Fargo building for $0.8 million on May 1, 2019. On the same day, we entered into an agreement with JS2L Partners, LLP, to lease this property for a term of 12 months . The base rental payments associated with the lease are $0.1 million in aggregate.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2018 , filed with the SEC on Form 10-K on March 1, 2019 , include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
Discontinued Operations	Discontinued Operations On February 1, 2018, the Company completed the sale of its customer contracts relating to the Medical Device Sales and Service (“MDSS”) post-warranty service business to Philips North America LLC (“Philips”) pursuant to an Asset Purchase Agreement, dated as of December 22, 2017 for $8.0 million . For all periods presented in our condensed consolidated statements of operations, all sales, costs, expenses, and income taxes attributable to MDSS, except as related to the impact of the decrease in the federal statutory tax rate (see Note 10 Income Taxes ), have been aggregated under the caption “earnings from discontinued operations, net of income taxes.” Cash flows used in or provided by MDSS operations as part of discontinued operations are disclosed in Note 2 Discontinued Operations . Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate to our continuing operations.
Use of Estimates	Use of Estimates Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.
Leases	Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and operating lease liabilities, net of current portion in our condensed consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit discount rate when readily determinable; however, as most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease valuation may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components of its operating leases in which it is the lessee and lessor. Additionally, The Company elected not to recognize right-of use assets and leases liabilities that arise from short-term leases of twelve months or less.
Recently Adopted and Recently Issued Accounting Standards	Recently Adopted Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amended the existing accounting standards for the accounting for leases. Most significant among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases under current U.S. GAAP. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted ASC 842 beginning January 1, 2019, using the modified-retrospective method, which will result in a cumulative effect adjustment to accumulated deficit at the beginning of 2019, rather than adjustments to the comparative prior periods presented in the financial statements. In connection with the adoption, the Company has elected to utilize the package of practical expedients, including: (1) not reassess the lease classification for any expired or existing leases, (2) not reassess the treatment of initial direct costs as they related to existing leases, and (3) not reassess whether expired or existing contracts are or contain leases. Upon adoption, the Company recorded right-of-use assets and lease liabilities on its condensed consolidated balance sheet $3.8 million and $3.9 million , respectively, primarily related to real estate and vehicle leases. See Note 6 Leases for further detail. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company early adopted ASU 2018-15 beginning January 1, 2019, and applied the guidance prospectively to the implementation costs incurred in the Net-Suite ERP implementation. As of March 31, 2019 , the Company has capitalized $29 thousand of implementation costs.
Revenue	Product and Product-Related Revenues and Services Revenue Product and product-related revenue are generated from the sale of gamma cameras and post-warranty maintenance service contracts within our Diagnostic Imaging reportable segment. Services revenue are generated from providing diagnostic imaging and cardiac monitoring services to customers within our Diagnostic Services and Mobile Healthcare reportable segments. Services revenue also includes lease income generated from interim rentals of imaging systems to our customers. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Taxes collected from customers, which are subsequently remitted to governmental authorities, are excluded from revenue. The majority of our contracts have a single performance obligation as we provide a series of distinct services that are substantially the same and are transferred with the same pattern to the customer. For contracts with multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost plus margin approach when one is not available. Our products are generally not sold with a right of return and the Company does not provide significant credits or incentives, which may be required for as variable consideration when estimating the amount of revenue to be recognized. Nature of Goods and Services Mobile Imaging Within our Diagnostic Services and Mobile Healthcare reportable segments, our sales are derived from providing services and materials to our customers, primarily physician practices and hospitals, that allow them to perform diagnostic imaging services at their site. We typically bundle our services in providing staffing, our imaging systems, licensing, radiopharmaceuticals, and supplies depending on our customers’ needs. Our contracts with customers are typically entered into annually and are billed on a fixed rate per-day or per-scan basis, depending on terms of the contract. For the majority of these contracts, the Company has the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company’s performance to date. The Company uses the practical expedient to recognize revenue corresponding with amounts we have the right to invoice for services performed. Camera Within our Diagnostic Imaging segment, camera revenues are generated from the sale of internally developed solid-state gamma camera imaging systems. We recognize revenue upon transfer of control to the customer, which is generally upon delivery and acceptance. We also provide installation services and training on cameras we sell, primarily in the United States. Installation and initial training is generally performed shortly after delivery. The Company recognizes revenues for installation and training over time as the customer receives and consumes benefits provided as the Company performs the installation services. Our sale of imaging systems includes a one -year warranty that we account for as an assurance-type warranty. The expected costs associated with our standard warranties and field service actions continue to be recognized as expense when cameras are sold. Maintenance service contracts sold beyond the term of our standard warranties are accounted for as a service-type warranty and revenue is deferred and recognized ratably over the period of the obligation. Camera Support Within our Diagnostic Imaging segment, camera support revenue is derived from the sale of separately-priced extended maintenance contracts to camera owners, training, and the sale of parts to customers that do not have an extended warranty. Our separately priced service contracts range from 12 to 48 months. Service contracts are usually billed at the beginning of the contract period or at periodic intervals (e.g., monthly or quarterly) and revenue is recognized ratably over the term of the agreement. Services and training revenues are recognized in the period the services and training are performed. Revenue for sales of parts are recognized when the parts are delivered to the customer and control is transferred. Lease Income Within primarily our Mobile Healthcare segment, we also generate income from interim rentals of our imaging systems to customers that are in the midst of new construction or refurbishing their current facilities. Rental contracts are structured as either a weekly or monthly payment arrangement and are accounted for as operating leases. Revenues are recognized on a straight-line basis over the term of the rental. Deferred Revenues We record deferred revenues when cash payments are received or due in advance of our performance, including amounts that are refundable. We have determined our contracts do not include a significant financing component. The majority of our deferred revenue relates to payments received on camera support post-warranty service contracts, which are billed at the beginning of the annual contract period or at periodic intervals (e.g., monthly or quarterly). The Company has elected to use the practical expedient under ASC 606 to exclude disclosures of unsatisfied remaining performance obligations for (i) contracts having an original expected length of one year or less or (ii) contracts for which the practical expedient has been applied to recognize revenue at the amount for which it has a right to invoice. Contract Costs We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs mainly include the Company’s internal sales commissions; under the terms of these programs these are generally earned and the costs are recognized at the time the revenue is recognized.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Information	The following table presents financial results of the MDSS business (in thousands): Three Months Ended March 31, 2019 2018 Total revenues $ — $ 624 Total cost of revenues — 516 Gross profit — 108 Operating expenses: Marketing and sales — 85 General and administrative — 172 Amortization of intangible assets — 13 Gain on sale of discontinued operations — (6,261 ) Total operating expenses — (5,991 ) Income from discontinued operations — 6,099 Interest expense — (26 ) Income from discontinuing operations before income taxes — 6,073 Income tax expense — (579 ) Income from discontinuing operations $ — $ 5,494 The following table presents supplemental cash flow information of discontinued operations (in thousands): Three Months Ended March 31, 2019 2018 Operating activities: Depreciation $ — $ 2 Amortization of intangible assets $ — $ 13 Gain on sale of discontinued operations $ — $ (6,261 ) Stock-based compensation $ — $ (1 ) Investing activities: Proceeds from the sale of discontinued operations $ — $ 6,844

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present our revenues for the three months ended March 31, 2019 and 2018 , disaggregated by major source (in thousands): Three Months Ended March 31, 2019 Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,585 $ — $ 7,494 $ 19,079 Camera — 804 — 804 Camera Support — 1,719 — 1,719 Revenue from Contracts with Customers 11,585 2,523 7,494 21,602 Lease Income 141 — 2,169 2,310 Total Revenues $ 11,726 $ 2,523 $ 9,663 $ 23,912 Timing of Revenue Recognition Services and goods transferred over time $ 11,726 $ 1,551 $ 9,525 $ 22,802 Services and goods transferred at a point in time — 972 138 1,110 Total Revenues $ 11,726 $ 2,523 $ 9,663 $ 23,912 Three Months Ended March 31, 2018 Diagnostic Services Diagnostic Imaging Mobile Healthcare Total Major Goods/Service Lines Mobile Imaging and Cardiac Monitoring $ 11,898 $ — $ 8,079 $ 19,977 Camera — 1,070 — 1,070 Camera Support — 1,744 — 1,744 Revenue from Contracts with Customers 11,898 2,814 8,079 22,791 Lease Income 127 28 2,519 2,674 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465 Timing of Revenue Recognition Services and goods transferred over time $ 10,964 $ 1,720 $ 10,491 $ 23,175 Services and goods transferred at a point in time 1,061 1,122 107 2,290 Total Revenues $ 12,025 $ 2,842 $ 10,598 $ 25,465
Changes in Deferred Revenue	Changes in the deferred revenues for three months ended March 31, 2019 , is as follows (in thousands): Balance at December 31, 2018 $ 1,713 Revenue recognized that was included in balance at beginning of the year (541 ) Deferred revenue, net, related to contracts entered into during the year 262 Balance at March 31, 2019 $ 1,434

Basic and Diluted Net Income _2

Basic and Diluted Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share, Basic and Diluted [Abstract]
Reconciliation of Shares Used to Compute Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the reconciliation of shares used to compute basic and diluted net (loss) income per share for the periods indicated (in thousands): Three Months Ended March 31, 2019 2018 Loss from continuing operations $ (1,657 ) $ (1,388 ) Income from discontinued operations — 5,494 Net (loss) income $ (1,657 ) $ 4,106 Weighted-average shares outstanding—basic and diluted 20,278 20,092 (Loss) income per common share—basic and diluted Continuing operations $ (0.08 ) $ (0.07 ) Discontinued operations — 0.27 Net (loss)income per common share—basic and diluted $ (0.08 ) $ 0.20
Schedule of Antidilutive Securities Excluded from Computation of Net Income (Loss) Per Share	The computation of diluted earnings per share excludes stock options and stock units that are anti-dilutive. The following common stock equivalents were anti-dilutive (in thousands): Three Months Ended March 31, 2019 2018 Stock options 1,000 207 Restricted stock units 287 129 Total 1,287 336

Supplementary Balance Sheet I_2

Supplementary Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories are as follows (in thousands): March 31, December 31, Inventories: Raw materials $ 2,425 $ 2,419 Work-in-process 2,285 2,307 Finished goods 1,154 1,056 Total inventories 5,864 5,782 Less reserve for excess and obsolete inventories (381 ) (380 ) Total inventories, net $ 5,483 $ 5,402
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): March 31, December 31, 2018 Property and equipment: Land $ 550 $ 550 Buildings and leasehold improvements 1,989 1,989 Machinery and equipment 52,138 52,409 Computer hardware and software 4,489 4,490 Total property and equipment 59,166 59,438 Less accumulated depreciation (38,591 ) (37,793 ) Total property and equipment, net $ 20,575 $ 21,645

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Lease Cost and Other Information	The components of lease expense are as follows (in thousands): Three Months Ended Operating lease cost $ 326 Finance lease cost: Amortization of finance lease assets $ 53 Interest on finance lease liabilities 33 Total finance lease cost $ 86 Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 287 Operating cash flows from finance leases $ 33 Financing cash flows from finance leases $ 184 Right-of-use assets obtained in exchange for lease obligations Operating leases $ 323 Finance leases $ 145
Schedule of Balance Sheet Information	Supplemental balance sheet information related to leases was as follows (in thousands): March 31, Operating lease right-of-use assets, net $ 3,681 Operating lease liabilities $ 1,251 Operating lease liabilities, net of current 2,564 Total operating lease liabilities $ 3,815 Finance lease assets $ 3,702 Finance lease accumulated amortization (1,100 ) Finance lease assets, net $ 2,602 Finance lease liabilities $ 809 Finance lease liabilities, net of current 1,607 Total finance lease liabilities $ 2,416 Weighted-Average Remaining Lease Term (in years) Operating leases 3.4 Finance leases 2.9 Weighted-Average Discount Rate Operating leases 5.00 % Finance leases 6.00 %
Schedule of Future Minimum Operating Lease Payments	The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2019 were as follows (in thousands): Operating Finance Leases 2019 (excludes the three-months ended March 31, 2019) $ 1,066 $ 696 2020 1,317 842 2021 953 817 2022 552 258 2023 259 10 Thereafter 4 — Total future minimum lease payments $ 4,151 $ 2,623 Less amounts representing interest 336 207 Present value of lease obligations $ 3,815 $ 2,416
Schedule of Future Minimum Finance Lease Payments	The future minimum lease payments due under both non-cancelable operating leases and finance leases having initial or remaining lease terms in excess of one year as of March 31, 2019 were as follows (in thousands): Operating Finance Leases 2019 (excludes the three-months ended March 31, 2019) $ 1,066 $ 696 2020 1,317 842 2021 953 817 2022 552 258 2023 259 10 Thereafter 4 — Total future minimum lease payments $ 4,151 $ 2,623 Less amounts representing interest 336 207 Present value of lease obligations $ 3,815 $ 2,416

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Financial Assets Measured at Fair Value on a Recurring Basis	The following table presents information about our financial assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2019 and December 31, 2018 (in thousands). Fair Value as of March 31, 2019 Level 1 Level 2 Level 3 Total Equity securities $ 17 $ 31 $ — $ 48 Fair Value as of December 31, 2018 Level 1 Level 2 Level 3 Total Equity securities $ 153 $ 6 $ — $ 159

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Summary of Long-Term Debt	A summary of long-term debt is as follows (in thousands): March 31, 2019 December 31, 2018 Amount Weighted-Average Interest Rate Amount Weighted-Average Interest Rate Revolving Credit Facility - SNB $ 12,517 5.00% $ — —% Revolving Credit Facility - Comerica $ — —% $ 9,500 4.87%

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment information is as follows (in thousands): Three Months Ended March 31, 2019 2018 Revenue by segment: Diagnostic Services $ 11,726 $ 12,025 Diagnostic Imaging 2,523 2,842 Mobile Healthcare 9,663 10,598 Condensed consolidated revenue $ 23,912 $ 25,465 Gross profit by segment: Diagnostic Services $ 2,581 $ 2,247 Diagnostic Imaging 786 1,245 Mobile Healthcare 614 1,115 Condensed consolidated gross profit $ 3,981 $ 4,607 Loss from continuing operations by segment: Diagnostic Services $ 1,736 $ 993 Diagnostic Imaging 343 619 Mobile Healthcare (623 ) (51 ) Unallocated corporate and other expenses (2,591 ) (3,170 ) Condensed consolidated loss from continuing operations $ (1,135 ) $ (1,609 ) Depreciation and amortization by segment: Diagnostic Services $ 304 $ 596 Diagnostic Imaging 78 74 Mobile Healthcare 1,427 1,592 Total depreciation and amortization $ 1,809 $ 2,262

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Jan. 01, 2019	Feb. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease, right-of-use asset				$ 3,800
Lease, liability				$ 3,900
Capitalized implementation costs		$ 29
Telerhythmics
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Consideration received	$ 1,950
Total rent payments	$ 200
Gain on sale of Telerhythmics			$ 19
Discontinued operations, disposed of by sale | MDSS post-warranty service business
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Consideration received					$ 8,000

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - MDSS post-warranty service business - Discontinued operations, disposed of by sale $ in Millions	Feb. 01, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received	$ 8
Held in escrow	$ 0.5

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Income from discontinuing operations	$ 0	$ 5,494
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues	0	624
Total cost of revenues	0	516
Gross profit	0	108
Operating expenses:
Marketing and sales	0	85
General and administrative	0	172
Amortization of intangible assets	0	13
Gain on sale of discontinued operations	0	(6,261)
Total operating expenses	0	(5,991)
Income from discontinued operations	0	6,099
Interest expense	0	(26)
Income from discontinuing operations before income taxes	0	6,073
Income tax expense	0	(579)
Income from discontinuing operations	$ 0	$ 5,494

Discontinued Operations - Suppl

Discontinued Operations - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of discontinued operations	$ 0	$ 6,844
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	0	2
Amortization of intangible assets	0	13
Gain on sale of discontinued operations	0	(6,261)
Stock-based compensation	0	(1)
Proceeds from sale of discontinued operations	$ 0	$ 6,844

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	$ 21,602	$ 22,791
Lease Income	2,310	2,674
Total revenues	23,912	25,465
Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	22,802	23,175
Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,110	2,290
Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	19,079	19,977
Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	804	1,070
Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,719	1,744
Diagnostic Services
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	11,585	11,898
Lease Income	141	127
Total revenues	11,726	12,025
Diagnostic Services | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	11,726	10,964
Diagnostic Services | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0	1,061
Diagnostic Services | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	11,585	11,898
Diagnostic Services | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0	0
Diagnostic Services | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0	0
Diagnostic Imaging
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	2,523	2,814
Lease Income	0	28
Total revenues	2,523	2,842
Diagnostic Imaging | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,551	1,720
Diagnostic Imaging | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	972	1,122
Diagnostic Imaging | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0	0
Diagnostic Imaging | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	804	1,070
Diagnostic Imaging | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	1,719	1,744
Mobile Healthcare
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	7,494	8,079
Lease Income	2,169	2,519
Total revenues	9,663	10,598
Mobile Healthcare | Services and goods transferred over time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	9,525	10,491
Mobile Healthcare | Services and goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	138	107
Mobile Healthcare | Mobile Imaging and Cardiac Monitoring
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	7,494	8,079
Mobile Healthcare | Camera
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	0	0
Mobile Healthcare | Camera Support
Disaggregation of Revenue [Line Items]
Revenue from Contracts with Customers	$ 0	$ 0

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Non-current deferred revenue	$ 20	$ 26
Camera
Disaggregation of Revenue [Line Items]
Warranty term	1 year
Diagnostic Imaging | Camera Support | Minimum
Disaggregation of Revenue [Line Items]
Service contract term	12 months
Diagnostic Imaging | Camera Support | Maximum
Disaggregation of Revenue [Line Items]
Service contract term	48 months

Revenue - Schedule of Changes i

Revenue - Schedule of Changes in Deferred Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Change In Contract With Customer, Liability [Roll Forward]
Balance at December 31, 2018	$ 1,713
Revenue recognized that was included in balance at beginning of the year	(541)
Deferred revenue, net, related to contracts entered into during the year	262
Balance at March 31, 2019	$ 1,434

Basic and Diluted Net Income _3

Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator:
Loss from continuing operations	$ (1,657)	$ (1,388)
Income from discontinued operations	0	5,494
Net (loss) income	$ (1,657)	$ 4,106
Denominator:
Weighted average shares outstanding – basic and diluted (in shares)	20,278	20,092
(Loss) income per common share—basic and diluted
Continuing operations (in usd per share)	$ (0.08)	$ (0.07)
Discontinued operations (in usd per share)	0	0.27
Net (loss) income per share—basic and diluted (in usd per share)	$ (0.08)	$ 0.20
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,287	336
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,000	207
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	287	129

Supplementary Balance Sheet I_3

Supplementary Balance Sheet Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 2,425	$ 2,419
Work-in-process	2,285	2,307
Finished goods	1,154	1,056
Total inventories	5,864	5,782
Less reserve for excess and obsolete inventories	(381)	(380)
Total inventories, net	$ 5,483	$ 5,402

Supplementary Balance Sheet I_4

Supplementary Balance Sheet Information - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 59,166	$ 59,438
Less accumulated depreciation	(38,591)	(37,793)
Total property and equipment, net	20,575	21,645
Land
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	550	550
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	1,989	1,989
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	52,138	52,409
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 4,489	$ 4,490

Leases - Narrative (Details)

Leases - Narrative (Details)	3 Months Ended
	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Option to terminate period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	6 years

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 326
Amortization of finance lease assets	53
Interest on finance lease liabilities	33
Total finance lease cost	$ 86

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 287
Operating cash flows from finance leases	33
Financing cash flows from finance leases	184
Right-of-use assets obtained in exchange for lease obligations, operating lease	323
Right-of-use assets obtained in exchange for lease obligations, finance lease	$ 145

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Balance Sheet Information (Details) $ in Thousands	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating lease right-of-use assets, net	$ 3,681
Operating lease liabilities	1,251
Operating lease liabilities, net of current portion	2,564
Total operating lease liabilities	3,815
Finance lease assets	3,702
Finance lease accumulated amortization	(1,100)
Finance lease assets, net	2,602
Finance lease liabilities	809
Finance lease liabilities, net of current	1,607
Total finance lease liabilities	$ 2,416
Operating lease, weighted-Average Remaining Lease Term (in years)	3 years 4 months 24 days
Financing leases, weighted-Average Remaining Lease Term (in years)	2 years 10 months 24 days
Operating leases, weighted-Average Discount Rate	5.00%
Financing leases, weighted-Average Discount Rate	6.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Lease Liabilities, Payments Due [Abstract]
2019 (excludes the three-months ended March 31, 2019)	$ 1,066
2020	1,317
2021	953
2022	552
2023	259
Thereafter	4
Total future minimum lease payments	4,151
Less amounts representing interest	336
Present value of lease obligations	3,815
Finance Lease Liabilities, Payments, Due [Abstract]
2019 (excludes the three-months ended March 31, 2019)	696
2020	842
2021	817
2022	258
2023	10
Thereafter	0
Total future minimum lease payments	2,623
Less amounts representing interest	207
Present value of lease obligations	$ 2,416

Financial Instruments - Financi

Financial Instruments - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Equity securities - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 48	$ 159
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	17	153
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	31	6
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 0	$ 0

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) $ in Thousands	Mar. 31, 2019USD ($)
Equity securities
Debt Securities, Available-for-sale [Line Items]
Unrealized gain	$ 28

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - Line of Credit - Revolving Credit Facility - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Credit Facility Due March 2024
Debt Instrument [Line Items]
Amount	$ 12,517	$ 0
Weighted-Average Interest Rate	5.00%	0.00%
Credit Facility Due June 2022
Debt Instrument [Line Items]
Amount	$ 0	$ 9,500
Weighted-Average Interest Rate	0.00%	4.87%

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Mar. 29, 2019	Mar. 31, 2019	Mar. 31, 2018
Line of Credit Facility [Line Items]
Debt issuance costs write-off		$ 151,000	$ 0
Line of Credit | Credit Facility Due March 2024 | SNB | Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt term	5 years
Maximum borrowing capacity	$ 20,000,000
Letters of credit (not to exceed)	$ 500,000
Borrowing availability		7,500,000
Line of Credit | Credit Facility Due March 2024 | London Interbank Offered Rate (LIBOR) | SNB | Revolving Credit Facility
Line of Credit Facility [Line Items]
Basis spread	2.50%
Additional margin rate	2.25%
Letter of Credit | SNB | Revolving Credit Facility
Line of Credit Facility [Line Items]
Letters of credit (not to exceed)		$ 100,000
Board of Directors Chairman
Line of Credit Facility [Line Items]
Obligations under the Limited Guaranty	$ 1,500,000

Income Tax (Details)

Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax benefit, continued operations	$ 8	$ 455
Unrecognized tax benefits	3,600
Unrecognized tax benefits that would impact effective tax rate	3,200
MDSS post-warranty service business | Discontinued operations, disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax expense, discontinued operations	$ 0	$ 579

Segments (Details)

Segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Condensed consolidated revenue	$ 23,912	$ 25,465
Condensed consolidated gross profit	3,981	4,607
Condensed consolidated loss from continuing operations	(1,135)	(1,609)
Total depreciation and amortization	1,809	2,262
Diagnostic Services
Segment Reporting Information [Line Items]
Condensed consolidated revenue	11,726	12,025
Condensed consolidated gross profit	2,581	2,247
Condensed consolidated loss from continuing operations	1,736	993
Total depreciation and amortization	304	596
Diagnostic Imaging
Segment Reporting Information [Line Items]
Condensed consolidated revenue	2,523	2,842
Condensed consolidated gross profit	786	1,245
Condensed consolidated loss from continuing operations	343	619
Total depreciation and amortization	78	74
Mobile Healthcare
Segment Reporting Information [Line Items]
Condensed consolidated revenue	9,663	10,598
Condensed consolidated gross profit	614	1,115
Condensed consolidated loss from continuing operations	(623)	(51)
Total depreciation and amortization	1,427	1,592
Unallocated corporate and other expenses
Segment Reporting Information [Line Items]
Condensed consolidated loss from continuing operations	$ (2,591)	$ (3,170)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Dec. 14, 2018	Jul. 27, 2015	Mar. 31, 2019	Mar. 29, 2019
Related Party Transaction [Line Items]
Investment made as part of Subscription Agreement		$ 1,000,000
Shares acquired (in shares)		71,429
Board of Directors Chairman
Related Party Transaction [Line Items]
Obligations under the Limited Guaranty				$ 1,500,000
ATRM Holdings, Inc. | Board of Directors Chairman
Related Party Transaction [Line Items]
Ownership percentage			17.40%
Series B Preferred Stock | Lone Star Value Investors, LP | ATRM Holdings, Inc.
Related Party Transaction [Line Items]
Shares owned (in shares)			222,577
Series B Preferred Stock | ATRM Holdings, Inc.
Related Party Transaction [Line Items]
Preferred stock, dividend rate percentage			10.00%
Series B Preferred Stock | Lone Star Value Co-Invest I, LP | ATRM Holdings, Inc.
Related Party Transaction [Line Items]
Shares acquired (in shares)			374,562
Star Procurement, LLC
Related Party Transaction [Line Items]
Joint venture interest	50.00%
Capital contribution	$ 1,000,000
ATRM Holdings, Inc. | Affiliated Entity
Related Party Transaction [Line Items]
Promissory note	$ 300,000
Minimum | ATRM Holdings, Inc. | Affiliated Entity
Related Party Transaction [Line Items]
Promissory note, interest rate	10.00%
Maximum | ATRM Holdings, Inc. | Affiliated Entity
Related Party Transaction [Line Items]
Promissory note, interest rate	12.00%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($) $ in Millions	May 01, 2019	Apr. 25, 2019	Apr. 03, 2019
Oxford Lease
Subsequent Event [Line Items]
Purchase price		$ 1.2
Initial term			120 months
Waterford Lease
Subsequent Event [Line Items]
Purchase price			$ 1
Initial term			120 months
Park Lease
Subsequent Event [Line Items]
Purchase price			$ 2.9
Initial term			120 months
Fargo Building
Subsequent Event [Line Items]
Purchase price	$ 0.8
Initial term	12 months
Base rental payments	$ 0.1
Minimum | Oxford Lease
Subsequent Event [Line Items]
Base rental payments			$ 1.4
Minimum | Waterford Lease
Subsequent Event [Line Items]
Base rental payments			1.2
Minimum | Park Lease
Subsequent Event [Line Items]
Base rental payments			3.3
Maximum | Oxford Lease
Subsequent Event [Line Items]
Base rental payments			1.5
Maximum | Waterford Lease
Subsequent Event [Line Items]
Base rental payments			1.3
Maximum | Park Lease
Subsequent Event [Line Items]
Base rental payments			$ 3.6